EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Extended Caffeine for Apnea in Moderately Preterm Infants

Waldemar A Carlo, Eric C Eichenwald, Benjamin A Carper, Edward F Bell, Martin Keszler, Ravi M Patel, Pablo J Sánchez, Ronald N Goldberg, Carl T D'Angio, Krisa P Van Meurs, Anna Maria Hibbs, Namasivayam Ambalavanan und 22 weitere

JAMA · 2025

DOI: 10.1001/jama.2025.5791 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, 2025. Verfasst von Waldemar A Carlo und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Neonatology, University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Apnea, Caffeine, Central Nervous System Stimulants, Citrates. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hospitalization of moderately preterm infants may be prolonged while waiting for apnea of prematurity to resolve after discontinuing caffeine.

Objective

To evaluate whether extending caffeine treatment reduces the duration of hospitalization. Design, Setting, and Participants From February 2019 to December 2022, this randomized clinical trial in 29 US hospitals enrolled infants born at 29 to 33 weeks’ gestation who at 33 to 35 weeks’ postmenstrual age were receiving caffeine treatment with plans to discontinue it plus receiving full feeds (≥120 mL/kg/d). Follow-up was completed on March 20, 2023.

Interventions

Infants were randomized to oral caffeine citrate (10 mg/kg/d) or placebo until 28 days after discharge. Main Outcomes and Measures The primary outcome was days to discharge after randomization. Secondary outcomes included days to physiological maturity (apnea free for 5 consecutive days, receiving full oral feeds, and out of the incubator for at least 48 hours), postmenstrual age at discharge, all-cause hospital readmissions, all-cause sick and emergency department visits, safety outcomes, and death.

Results

A total of 827 infants (median gestational age, 31 weeks; 414 female [51%]) were randomized (416, caffeine; 411, placebo) out of the 878 planned before reaching the prespecified futility threshold. Days of hospitalization after randomization did not differ between groups (18.0 days [IQR, 10 to 30 days] for caffeine vs 16.5 [IQR, 10 to 27 days] for placebo; adjusted median difference, 0 days [95% CI, −1.7 to 1.7 days]), nor did days to physiological maturity differ (14.0 vs 15.0 days, adjusted median difference, −1 day [95% CI, −2.4 to 0.4 days]). Infants receiving caffeine were apnea free sooner (6.0 vs 10.0 days; adjusted median difference, −2.7 days [95% CI, −3.4 to −2.0 days ]) but had similar days to full oral feeding (7.5 vs 6.0 days, adjusted median difference, 0 days [95% CI, −0.1 to 0.1]). Rates of readmissions and sick visits did not differ between groups. There was no statistically significant difference in adverse events between the 2 groups. Conclusions and Relevance In moderately preterm infants, continuation of caffeine treatment compared with placebo did not shorten hospitalization. Trial Registration ClinicalTrials.gov Identifier: NCT03340727

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApneaCaffeineCentral Nervous System StimulantsCitratesInfant, Premature, DiseasesFemaleHumansInfant, NewbornMaleGestational AgeInfant, PrematureLength of StayPatient ReadmissionAdministration, OralTreatment OutcomeTime FactorsMaternal AgeAdult

Substanzen

Caffeinecaffeine citrateCentral Nervous System StimulantsCitrates

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Neonatology, University of Alabama at Birmingham.
  • Hospital of the University of Pennsylvania (HUP), Children's Hospital of Philadelphia, Philadelphia.
  • RTI International, Research Triangle Park, North Carolina.
  • Department of Pediatrics, University of Iowa, Iowa City.
  • Women and Infants Hospital of Rhode Island, Department of Pediatrics, Brown University, Providence.
  • Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia.

Förderung

  • NICHD NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Carlo, W. A., Eichenwald, E. C., Carper, B. A., Bell, E. F., Keszler, M., Patel, R. M., Sánchez, P. J., Goldberg, R. N., D'Angio, C. T., Van Meurs, K. P., Hibbs, A. M., Ambalavanan, N., Cosby, S. S., Newman, N. S., Vohr, B. R., Walsh, M. C., Das, A., Ohls, R. K., Fuller, J., …, & Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2025). Extended Caffeine for Apnea in Moderately Preterm Infants. JAMA. https://doi.org/10.1001/jama.2025.5791

Vancouver

Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, et al. Extended Caffeine for Apnea in Moderately Preterm Infants. JAMA. 2025. doi:10.1001/jama.2025.5791

BibTeX
@article{Carlo2025,
  author = {Carlo, Waldemar A and Eichenwald, Eric C and Carper, Benjamin A and Bell, Edward F and Keszler, Martin and Patel, Ravi M and Sánchez, Pablo J and Goldberg, Ronald N and D'Angio, Carl T and Van Meurs, Krisa P and Hibbs, Anna Maria and Ambalavanan, Namasivayam and Cosby, Shirley S and Newman, Nancy S and Vohr, Betty R and Walsh, Michele C and Das, Abhik and Ohls, Robin K and Fuller, Janell and Rysavy, Matthew A and Ghavam, Sarvin and Brion, Luc P and Puopolo, Karen M and Moore, Ryan and Baack, Michelle L and Colaizy, Tarah T and Baserga, Mariana and Osman, Ahmed F and Merhar, Stephanie L and Poindexter, Brenda B and DeMauro, Sara B and Kumar, Vasanth and Cotten, C Michael and Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network},
  title = {Extended Caffeine for Apnea in Moderately Preterm Infants},
  journal = {JAMA},
  year = {2025},
  doi = {10.1001/jama.2025.5791}
}
Kostenlos starten →